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tion, the mice have normal body weight, adipos-
ity, locomotor activity, and glucose homeostasis, 
similar to the findings in the patient.
The data from these transgenic mice support 
the authors’ supposition that nonclassical regu-
lation of estrogen receptor α is sufficient to 
protect against the obesity–metabolic syndrome 
phenotype associated with a total loss of activity 
of estrogen receptor α but is not sufficient to 
rescue the infertility phenotype. We offer the 
murine findings as support of the authors’ initial 
claims, and we believe these findings further 
implicate a differential role for classical versus 
nonclassical activity of estrogen receptor α in the 
regulation of energy and reproductive homeostasis.
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The authors reply: Similarities between the 
correspondents’ transgenic mice and our patient 
with estrogen resistance (with both showing im-
paired classical estrogen signaling) are important 
because they reaffirm the relevance of murine 
models in the study of human disease. Studies in 
both Esr1 knockout and knock-in transgenic mice 
indicate that the function of estrogen receptor α 
not only is important in reproduction but also is 
key in energy regulation.1,2 These important 
findings, which would be challenging to study in 
humans, have confirmed translational relevance, 
as shown in our estrogen-resistant patient. The 
prevalence of ESR1 mutations in the general pop-
ulation is unknown, but given the murine and 
human phenotypes, more persons with such mu-
tations may be identified in the future. Our find-
ings confirm the existence of ESR1 mutations in 
women, which contradicts previous assertions that 
the absence of function of estrogen receptor α 
would be lethal in women.3 Together, the mouse 
models and long-term follow-up of our patient, 
as well as newly identified estrogen-resistant 
patients, will be important in the study of the 
longitudinal consequences of absent classical 
estrogen signaling.
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Acute High-Altitude Illnesses
To the Editor: Bärtsch and Swenson (June 13 
issue)1 refer to our study assessing risk factors 
for severe high-altitude illnesses2 and conclude 
that physiological measurements “add little to 
the discrimination provided by patient . . . his-
tory.” In our prospective study involving clinical 
and physiological evaluation of a large cohort of 
persons before their stay at high altitudes,2 we 
found that adding physiological variables to a 
multivariate prediction model that included clin-
ical risk factors for severe high-altitude illnesses 
improved the accuracy of the prediction (the 
C-statistic increased from 0.81 to 0.88; P<0.001). 
Moreover, a great proportion of persons who 
present for a consultation with a specialist in 
mountain medicine (45%) have never been to high 
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altitudes before,2 so clinical information about a 
history of severe high-altitude illnesses is not 
available; this reinforces the usefulness of mea-
suring the ventilatory response to hypoxia.3 The 
test to assess the response to hypoxic conditions 
during exercise is inexpensive (€100, or $135 in 
2013 U.S. dollars), reproducible,4 and brief (<20 
minutes). In contrast to the authors’ assertion 
that “there are currently no reliable tests to pre-
dict . . . high-altitude illnesses,” we recommend 
this test for persons who are preparing to travel 
to high-altitude regions.
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To the Editor: Bärtsch and Swenson suggest 
that an age younger than 46 years is a risk factor 
for acute mountain sickness. This statement is 
not supported by data from controlled studies 
showing that the prevalence of acute mountain 
sickness after rapid ascent by train to 3500 m was 
roughly 50% lower in children than in adults.1,2 
Moreover, and in contrast to a history of acute 
mountain sickness in adults, a history of this ill-
ness in children had no predictive value for recur-
rence of the condition during subsequent expo-
sure; this suggests that a history of acute mountain 
sickness in children should not prompt practi-
tioners to advise against reexposure or prescribe 
drugs for prophylaxis against this condition.2
The authors also recommend the use of tadalafil 
for prophylaxis against high-altitude pulmonary 
edema. This recommendation is basically sound, 
since defective nitric oxide synthesis underpins the 
susceptibility to this problem.3 However, in what is 
to our knowledge the only controlled study of 
tadalafil involving high-altitude climbers, this 
agent induced severe acute mountain sickness that 
necessitated descent in 20% of the participants.4 
Tadalafil is not ideal for a prophylactic treatment, 
particularly since alternatives exist.3
Urs Scherrer, M.D. 
Emrush Rexhaj, M.D. 
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To the Editor: High-altitude retinal hemor-
rhage occurs frequently during mountain climb-
ing because of hypoxic dilation of retinal veins 
and increased retinal venous pressure secondary 
to physical exertion and coughing.1 The prospec-
tive climber of Mount Kilimanjaro (5895 m) de-
scribed in the article by Bärtsch and Swenson 
faces a considerable risk of high-altitude retinal 
hemorrhage, in addition to acute mountain sick-
ness, high-altitude pulmonary edema, and high-
altitude cerebral edema.2 In prospective studies 
involving high-altitude climbers, high-altitude 
retinal hemorrhage was observed in 60 to 74% of 
persons.2,3 This condition may occur either dur-
ing the climb or after the descent. Although high-
altitude retinal hemorrhage is frequently asymp-
tomatic and resolves spontaneously, any decrease 
in visual acuity may signal extensive bleeding or 
macular involvement and should prompt imme-
diate accompanied descent.4 Occasionally, perma-
nent scotomata result. Unfortunately, neither slow 
acclimatization to high altitudes nor drug pro-
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phylaxis with the use of acetazolamide, gluco-
corticoids, or calcium-channel blockers prevents 
high-altitude retinal hemorrhage. This patient 
should be advised of the ocular hazards of his 
proposed ascent to high altitudes and should 
have an ophthalmologic examination after de-
scent to identify resolving high-altitude retinal 
hemorrhage and any residual visual defect.
E. Sage Colombo, M.D., Ph.D.
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To the Editor: Bärtsch and Swenson conclude 
that the efficacy of acetazolamide in the preven-
tion of acute mountain sickness during fast 
climbs is unknown. At least one excellent study1 
on Mount Rainier clearly showed that 750 mg of 
acetazolamide prevented acute mountain sickness 
during a rapid ascent of this mountain. Bärtsch 
and Swenson cite another study2 that showed 
that even a dose of 125 mg twice daily prevented 
acute mountain sickness during a rapid ascent 
from 1600 to 4300 m. They mention another 
study3 of a Mount Kilimanjaro climb that did not 
show any efficacy of 500 mg of acetazolamide in 
the prevention of acute mountain sickness, but it 
was not a randomized, controlled trial.
Finally, a marathon runner is featured in the 
case vignette. Anecdotally, in the Himalayas, 
trekkers who exercise strenuously at sea level 
often appear to be more prone to acute moun-
tain sickness because they may also exert them-
selves at high altitudes, and such exertion at high 
altitudes may be counterproductive.4
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The Authors Reply: We are aware of the unique 
prospective study by Richalet and colleagues. 
However, their recommendations are based on 
the response of only one third of the tested per-
sons, who returned self-reported information 
about a subsequent exposure to high altitudes. 
Selection bias due to a low response rate, lack of 
medical documentation of illness, and possible 
recall bias regarding medication and ascent 
rates limit the generalizability of the study by 
Richalet and colleagues. Furthermore, we con-
sider a 7.3 percentage-point increase in prediction 
accuracy due to the addition of physiological 
measurements as being small. Moreover, this 
epidemiologic study does not address how to 
translate saturation, ventilation, and heart rate 
measured during hypoxic exercise into specific 
recommendations. Before proposing physiologi-
cal assessments in advance of climbing, additional 
prospective data are needed to show that adding 
them to the approach summarized in our review 
improves the clinical outcome significantly.
The conclusion of Scherrer et al. that children 
are less susceptible to acute mountain sickness 
than adults is based on one study. In contrast, in 
two studies, reported prevalence rates of acute 
mountain sickness among children in various 
mountain areas were not appreciably different 
from those reported among adults in compara-
ble settings,1,2 and in one direct comparison, the 
rates appeared higher among children than 
among adults.3 The poor reproducibility of acute 
mountain sickness in the study cited by Scherrer 
et al. could in part be explained by factors such 
as travel, anxiety, and disruption of daily routine 
to which particularly younger children are very 
susceptible (as shown by a report of a 21% fre-
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quency of “acute mountain sickness” at a sea-
level summer camp).2 Finally, headache asso-
ciated with tadalafil is one reason why we 
consider phosphodiesterase-5 inhibitors as sec-
ond-line drugs to the calcium-channel blocker 
nifedipine, which is cheaper and better evaluated 
for the prevention and treatment of high-altitude 
pulmonary edema.
We did not mention high-altitude retinal 
hemorrhages because, as Colombo and Hoffman 
state, they usually do not pose a health problem 
for climbers and their occurrence is not influ-
enced by preventive measures for acute high-
altitude illnesses. We agree with their recommen-
dation for mountaineers, who have an acute loss 
of visual acuity at high altitudes.
The studies on acetazolamide cited by Basnyat 
do not address the situation of climbing rapidly 
to areas with very high altitudes such as Mount 
Kilimanjaro, since the final altitude in these 
studies was at most 4392 m. Two studies cited in 
our review showed no correlation between maxi-
mal oxygen uptake and the development of acute 
mountain sickness; this suggests that other fac-
tors account for the anecdotal observations in 
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Deficiency in Complement Factor B
To the Editor: The alternative complement path-
way is essential for defense against infection by 
polysaccharide-encapsulated bacteria. Factor B, 
factor D, and properdin are required to stably 
initiate the process.1 Deficiencies of factor D and 
properdin have been described in humans.2-4 
Here, we describe a 32-year-old woman with re-
current pneumococcal and meningococcal infec-
tion in whom factor B deficiency was detected.
The patient had nonconsanguineous parents 
of English and Scottish heritage. Her medical 
history revealed four clinically significant infec-
tions dating from childhood. At 2 years of age, 
she had primary pneumococcal peritonitis. Two 
years later, she was treated for community- 
acquired pneumonia. At 15 years of age, menin-
gitis (caused by Neisseria meningitidis, serogroup Y) 
developed. At age 30 years, pneumococcal pneu-
monia complicated by a unilateral empyema de-
veloped. She required prolonged admission to the 
intensive care unit for type 1 respiratory failure 
that prompted suspicion of an immunodeficiency, 
and she underwent a thoracotomy to drain the 
empyema.
Screening tests revealed normal immunoglob-
ulins and lymphocyte subsets. Classical comple-
ment pathway activity was normal, but accord-
ing to the results of a functional enzyme-linked 
immunosorbent assay (ELISA) (Wieslab, Euro Di-
agnostica), the alternative pathway was inactive.
Complement-mixing studies showed that the 
activity of the alternative pathway was restored 
to the patient’s serum by properdin-deficient se-
rum but not when the patient’s serum was mixed 
with commercially sourced factor B–depleted se-
rum. Factor B was undetectable by means of ra-
dial immunodiffusion (Binding Site) and ELISA 
(<36 g per liter; reference range, 119 to 245).
Genome sequencing of all 18 coding exons of 
the CFB gene (transcript NM_001710.5) revealed 
compound heterozygous mutations that resulted 
in premature stop codons (protein truncation): 
a nonsense mutation (p.Q256X, c.766C→T) in 
exon 6 and a frameshift mutation (p.F632CfsX8, 
c.1894_1897delTTTG) in exon 15 (Fig. 1).
The patient’s father was found to carry the 
c.1894_1897delTTTG mutation in exon 15. Her 
mother and sister carried the c.766C→T mutation 
in exon 6. Her two children were both in excellent 
health; testing to ascertain which of the patient’s 
mutations had been inherited by the children 
was deferred until they are older. Results of 
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